Law firm probes Novartis over possible securities fraud after trial failure drops shares 14%.

Pomerantz LLP is investigating Novartis and some of its executives for potential securities fraud following the company's announcement that its Phase III trial for a myotonic dystrophy drug failed to meet primary endpoints. The news caused Novartis's American Depositary Shares to fall nearly 14% on September 8, 2026. The investigation aims to determine if there were any unlawful business practices or misleading statements that affected investors. This legal scrutiny could lead to a class action lawsuit and further impact the company's reputation and stock price.

Novartis AG (NVS) shares are trading at USD 142.94 on Pluang as of Oct 14, 2026 04:51 WIB, which is closer to its 52-week low of USD 121.80 than its high of USD 168.62. The stock has seen a modest 1-day decline of 0.63%, contrasting with the nearly 14% drop reported on September 8, 2026. Investor sentiment on Pluang shows a strong sell bias with 82% of orders being sell and only 18% buy, reflecting cautious positioning after recent negative news.